{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-062628","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.300840+00:00","generated_at":"2026-06-12T11:45:41.575658+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ABVC signs binding term sheet for China license of MDD/ADHD drugs; up to $20M in fees plus royalties","bullets":["Binding term sheet with Xinnovation Therapeutics for exclusive license of ABV-1504 (MDD) and ABV-1505 (ADHD) in mainland China.","Potential aggregate income of $20M in licensing fees plus royalties of 5-12% of net sales.","Final definitive agreement expected within one year; subject to due diligence, regulatory approvals, board approval.","Xinnovation will bear all costs for clinical trials and product registration in China.","ABVC states royalty revenue could reach ~$50M annually and ~$1B over patent life if expected sales achieved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-062628","json":"https://secwatch.observer/filing/0001213900-23-062628.json","markdown":"https://secwatch.observer/filing/0001213900-23-062628.md","text":"https://secwatch.observer/filing/0001213900-23-062628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023062628/0001213900-23-062628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023062628/ea182689-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:45:41.575658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"943fad2b02a9b4afae5edd6ef1d444d212a3340b","claim":"ABVC BIOPHARMA, INC. entered into Term Sheet with Xinnovation Therapeutics Co., Ltd. (effective 2023-07-31).","evidence_excerpt":"On July 31, 2023, the Company entered into a binding term sheet (the “Term Sheet”) with Xinnovation Therapeutics Co., Ltd., a Company incorporated under the Law of People’s Republic of China (“Xinnovation”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023062628/0001213900-23-062628-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Xinnovation Therapeutics Co., Ltd."},{"label":"Effective","value":"2023-07-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}